Work

Increased Number of Prior Therapies and/or Use of Mismatched Unrelated Donors Adversely Affect Allogeneic Hematopoietic Cell Transplantation (alloHCT) Outcomes in Relapsed/Refractory Hodgkin Lymphoma (HL)

Year: 2013

Type: article

Abstract: Prognosis is poor for patients (pts) with refractory HL or for those who relapse following autologous HCT (autoHCT). Current salvage options aside from alloHCT remain palliative but the role, timing and utility of alloHCT is not clear. We report outcomes of 19 consecutive pts (Table 1) with relapsed/refractory HL receiving alloHCT between 2005 and 2011 at Moffitt Cancer Center. Data were obtained from the BMT database and supplemented with chart review. Disease responses are based on Cheson criteria (JCO 2007) and chemotherapy sensitivity is defined as PR or better at time of alloHCT.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2012.11.299